I.d.m. Immuno-designed Molecules

Other

I.d.m. Immuno-designed

Jacques Bartholeyns

Mohamed Chokri

Jean-Loup Romet-Lemonne

Yves Fouron

Marc Gregoire

Bernard Klein

Zhao Yang Lu

Nathalie Latour

The invention relates to humanized biomaterial comprising a porous biocompatible composite material customized and implanted with monocyte derived cells preferably with macrophages.

Humanized biomaterials, a process for their preparation and their applications

The invention relates to macrophages which have at least one of the following properties: their cytotoxic activity without IFN-&ggr; is increased by about 20 to 30% with respect to standard macrophages, and is preferably of about 70%; their cytotoxic activity with IFN-&ggr; is increased by about 20 to about 40% with respect to standard macrophages, and is preferably of about 93%; the extension of the deactivation of the cytotoxic activity in reply to an activation of IFN-&ggr; is in a ratio such that after 60h of activation with IFN-&ggr;, the cytotoxic activity is higher than or equal to 30%, preferably of about 55%, compared to the maximum cytotoxic activity presented by the macrophages due to IFN-&ggr; activation, with said cytotoxic activity being measured as the percentage of inhibition of 3-H thymidine incorporation by target tumoral cells, particularly U 937 cells.

Macrophages, process for preparing the same and their use as active substances of pharmaceutical compositions

The invention relates to a cell composition containing macrophages, presenting anti-infectious and hematopoietic properties. More particularly, the invention relates to a cell composition containing macrophages, myeloid cells and progenitors; said cell compositions are useful for the restoration of hematopoiesis in an aplasic patient and/or the protection of patients against infectious diseases or against residual tumors.

Cell compositions containing macrophages, presenting anti-infectious and hematopoietic properties

The present invention relates to combined preparation containing as active substance the following individual components, in the form of a kit-of-parts: monocyte derived cells, particularly cytotoxic macrophages, chemotherapy or immunotherapy drugs, for the simultaneous, separate or sequential use, for the treatment of cancer or infectious diseases.

Combined preparation for the treatment of neoplasic diseases or of infectious diseases

The present invention relates to apoptotic bodies derived from human tumor cells or cell lines recovered from patient's tumor biopsy and induced to apoptotis, said apoptotic bodies having the following characteristics: they maintain plasma membrane integrity, they are vesicles above about 0,1 &mgr;m, they contain intact mitochondria and cleaved nuclear DNA originating from the tumor cells, they present unmasked tumor antigens on their membranes, they present specific tumor and MHC antigens from the patient. The invention also provides new monocytes derived cells, which can be used as anti-tumor vaccines after integration of apoptotic bodies. Apoptotic bodies are phagocytosed and processed by monocyte derived antigen presenting cells and potentiate the effective tumor antigenic presentation to the immune system.

Apoptotic bodies, monocyte derived cells containing the same, a process for their preparation and their uses as vaccines

Monocyte derived cells with immunosuppressive properties including an increase in at least one of the following PGE-2, IL-10 and IL-4. Monocyte derived cells with a decreased level of expression and secretion of inflammatory and immunostimulating cytokines and a decrease on the membrane of activation or accessory molecules in the presence of polylysine-cDNA in the nucleus of the monocyte derived cells.

Monocyte derived cells with immunosuppressive properties, process for their preparation and their uses in pharmaceutical compositions

The invention relates to macrophages which have at least one of the following properties: their cytotoxic activity without IFN-7 is increased by about 20 to 30% with respect to standard macrophages, and is preferably of about 70%; their cytotoxic activity with IFN-&ggr; is increased by about 20 to about 40% with respect to standard macrophages, and is preferably of about 93%; the extension of the deactivation of the cytotoxic activity in reply to an activation of IFN-&ggr; is in a ratio such that after 60h of activation with IFN-&ggr;, the cytotoxic activity is higher than or equal to 30%, preferably of about 55%, compared to the maximum cytotoxic activity presented by the macrophages due to IFN-&ggr; activation, with said cytotoxic activity being measured as the percentage of inhibition of 3-H thymidine incorporation by target tumoral cells, particularly U 937 cells.

The invention relates to stimulated monocyte derived cells presenting the following characteristics: 1) increased release, with respect to normal monocyte derived cells, of for instance PDGF (platelet derived growth factor), and increased presence, on their membranes, with respect to normal monocyte derived cells, of for instance CD1&agr;, and/or: 2) presence in their nucleus of at least one exogenous nucleic acid which has been integrated in the absence of the monocyte derived cell division. These stimulated monocyte derived cells can be the active substance of pharmaceutical compositions.

Monocyte derived cells with immunostimulating properties, their preparation and uses

The invention relates to macrophages which have at least one of the following properties: their cytotoxic activity without IFN-.gamma. is increased by about 20 to 30% with respect to standard macrophages, and is preferably of about 70%; their cytotoxic activity with IFN-.gamma. is increased by about 20 to about 40% with respect to standard macrophages, and is preferably of about 93%; the extension of the deactivation of the cytotoxic activity in reply to an activation of IFN-.gamma. is in a ratio such that after 60 h of activation with IFN-.gamma., the cytotoxic activity is higher than or equal to 30%, preferably of about 55%, compared to the maximum cytotoxic activity presented by the macrophages due to IFN-.gamma. activation, with said cytotoxic activity being measured as the percentage of inhibition of 3-H thymidine incorporation by target tumoral cells, particularly U 937 cells.

Growing community of inventors

Bures-sur-Yvette, France

Jacques Bartholeyns